Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin
ConclusionsCBDCA or Cmab as a concurrent systemic therapy with RT is a possible treatment option for LASCCHN patients ineligible for CDDP treatment, although attention to hematological toxicity should be paid.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Carcinoma | Dermatitis | Dermatology | Erbitux | Head and Neck Cancer | Hematology | Hypopharyngeal Cancer | Japan Health | Neurology | Oral Cancer | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Thrombocytopenia | Toxicology